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ABSTRACT 
 
In more than 95% of patients, the Ewing family of tumors (ET) has chimeric transcripts 
caused by fusion of the EWS gene to either FLI1 or ERG. The presence of specific 
EWS-FLI1 or EWS-ERG transcripts in peripheral blood (PB) samples of patients being 
treated for ET was prospectively evaluated, and these data were correlated to their 
clinical status. The authors studied 113 PB samples from 28 patients with ET. 
Treatment included chemotherapy, radiotherapy, and surgical excision of tumor after 
induction therapy. PB samples were taken prospectively at least 2 weeks after resection 
of tumor. Nested reverse-transcriptase polymerase chain reaction (RT-PCR) followed 
by Southern blot was performed in all samples. Resected tumors were reviewed for the 
degree of response to chemotherapy and volume. Seventy-seven PB samples from 28 
patients had EWS-FLI1/ERG transcripts. In 11 patients, PB samples became negative 
with treatment, and, in 5 of them, the samples remained negative throughout the study. 
Samples taken during progression were always positive and, in 4 patients, became 
positive before progression was clinically evident. All patients with transcripts other 
than EWS-FLI1 type 1 (n = 3) died from tumor progression. This is a sensitive assay to 
monitor circulating tumor cells in Ewing tumors. The preliminary data suggest that 
progression is preceded by positive samples and may be related to specific transcript 
types. 
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INTRODUCTION 
 
The Ewing sarcoma family of tumors (ET) is defined by the presence of a gene fusion 
involving the EWS gene and a member of the ETS family of transcription factors, 
usually FLI1 or ERG (5). This entity includes Ewing's sarcoma/primitive peripheral 
neuroectodermal tumor of bone and soft tissues, and several special clinicopathologic 
presentations (i.e. Askin tumor). Stage at diagnosis remains the main prognostic factor 
in ET for disease-free and overall survival (23). Metastases at diagnosis, which are 
usually detected by imaging techniques, occur in approximately 15% to 25% of patients 
(9,23) and are associated to a poor prognosis. Neoadjuvant therapy, combining systemic 
control by chemotherapy with local control by surgery and radiotherapy, has 
dramatically improved survival rates. Moreover, initial response to therapy, usually 
assessed histologically on surgical specimens as the degree of tumor viability 
(19,23,26), has become another major independent prognostic factor, especially in 
localized tumors of the extremities. 
 
Gene fusions in ET are transcribed into chimeric transcripts, which can be detected 
using reverse-transcriptase polymerase chain reaction (RT-PCR) in over 95% of 
patients. Their detection is helpful in the diagnosis of ET (7,13,22). It has been recently 
reported that patients with EWS-FLI1 type 1 transcripts have a better prognosis than all 
other patients, regardless of other prognostic factors (2). 
 
The high sensitivity of PCR allows the detection of as little as 1 tumor cell in 106 
normal cells (7). Consequently, several groups have reported detection of tumor cells in 
peripheral blood (PB) and bone marrow (BM) samples of patients with ET 
(17,18,24,27). Those studies could be potentially useful to assess the initial response to 
treatment and the presence of minimal residual disease during and after treatment. 
 
Contradictory results have been reported regarding the value of RT-PCR performed on 
BM samples of patients with ET at the time of diagnosis to predict relapses (8,29). 
However, BM involvement in ET has been reported to be probably multifocal (15). 
Therefore, in contrast to previous approaches, we studied serial PB samples during and 
after therapy and correlated the presence of circulating tumor cells with other prognostic 
factors, including stage at diagnosis, histologic response to therapy, transcript type, and 
clinical outcome. 
 
 
 
MATERIALS AND METHODS 
 
Twenty-eight patients with ET (14 males and 14 fe-males, mean age 12.3 y, range, 3 to 
18 y), were included in this prospective study. Using standard criteria, 22 tumors were 
diagnosed as Ewing's sarcomas, and 6 were diagnosed as primitive peripheral 
neuroectodermal tumors (24). Five patients (patients 1 to 5) had metastatic disease at 
diagnosis; in the other 23 patients (patients 6 to 28), tumors were localized. Fifteen 
tumors were located in the extremities and 13 in the central axis. All patients were 
diagnosed and treated at Clínica Universitaria de Navarra, Pamplona, Spain. 
Multimodal therapy included chemotherapy (52 weeks, 18 cycles based on VAC 
[vincristine, actinomycin, and cyclophosphamide] plus ifosfamide), radiotherapy, and 
surgical excision (Fig. 1). Induction of treatment included 12 weeks of chemotherapy, 5 
weeks of radiotherapy, and surgical resection of tumor 5 weeks after radiotherapy. 
Chemotherapy continued after induction up to 18 cycles (approximately 40 more 
weeks). 
 
This study included 113 PB samples. PB samples always were taken at admission of the 
patient immediately before administration of a chemotherapy cycle. Because blood 
contamination by ET cells released during surgical procedures has been reported (30), 
we began to collect samples after induction and at least 2 weeks after tumor resection. 
Four ml of EDTA-treated whole blood were centrifuged on a Ficoll gradient (25 
minutes, 1000 g). The mononuclear cell layer was used for RNA extraction. In addition, 
samples of the primary tumors were available for molecular study in all patients. 
Informed consent was obtained from the patients or their guardians. and the Local 
Ethics Committee approved the protocol. 
  
Surgical resection specimens were available for histologic study in 20 patients. Two 
independent observers evaluated tumor necrosis on the surgical specimens. A whole 
section of the tumor was studied, including an average of 8 blocks. The tumors were 
graded according to the following system (19): grade 1, a tumor in which in gross 
examination at least one nodule of viable tumor is seen; grade 2, a tumor with only 
isolated microscopic foci of viable tumor cells; and grade 3, no viable tumor can be 
found. Tumor volume was calculated based either on the imaging studies (computed 
tomography and magnetic resonance imaging) or on the tumor resection specimens. 
Volume calculation formulas for elliptical (bony) and spheroidal (soft tissue) tumors are 
described in detail elsewhere (19). 
 
 
Molecular Study 
 
Extraction of total RNA was based on a modified guanidinium isothiocyanate-phenol 
chloroform method using the TRIZOL (Gibco BRL) reagent. An assay was designed 
including a nested RT-PCR using appropriate primers for EWS and FLI1/ERG genes. 
Primers have been described elsewhere (3,18) and are listed in Table 1. The assay was 
performed using 1 µg of total RNA as template and a GeneAmp RNA-PCR Kit (Perkin-
Elmer, Roche Molecular Systems, Branchburg, NJ, U.S.A.) following the manufacturer' 
s recommendations. Reverse transcription included an incubation period of 45 min at 
42°C with random hexamers followed by a 5-min period at 99°C to denature the 
enzyme. MgC12 concentration in the RT was 5 mM. PCR was then performed with an 
initial denaturation step of 95°C for 2 min, followed by 35 cycles including a 
denaturation step at 94°C for 30 sec, annealing at 66°C (68°C for the second round) for 
30 sec, and extension at 72°C for 60 sec, with 7 min of extension after the completion of 
the last cycle. A second round of amplification was performed using one-fifth of the 
initial PCR product with a second set of specific internal primers (see Table 1). Products 
were first analyzed by a 1% agarose gel electrophoresis and ethidium bromide staining. 
MgC12 concentration in both PCRs was 1.25 mM. All PCR products were then blotted 
onto nylon membranes (Hybond+; Amersham Pharmacia Biotech, Amersham, U.K.), 
and detected with internal probes (see Table 1) labeled with chemoluminescence (3' 
oligolabelling system; Amersham Pharmacia Biotech). EWS-FLI1 type 1 (EWS exon 7 
joined in frame with exon 6 of FLI1), type 2 (EWS exon 7 joined in frame with exon 5 
of FLI1), and EWS-ERG were typed according to the size of the RT-PCR products on 
the agarose gels and Southern blots. EWS-FLI1 7-7 products (EWS exon 7 joined in 
frame with exon 7 of FLI1) were sequenced (21). Negative controls lacking either tumor 
RNA or reverse transcriptase were routinely used. 
 
 
Statistical Study 
 
Statistical tests included Pearson chi-square test and Fisher exact test for qualitative 
parameters and one-way ANOVA to compare qualitative parameters and tumor volume. 
They were performed using the SPSS statistical package, version 6.0 for Windows 
(SPSS, Chicago, IL, U.S.A.). 
 
 
 
RESULTS 
 
Molecular Results  
 
Primary tumors 
Primary tumors showed EWS-FLI1 type 1 fusions in 25 patients (Table 2). One patient 
(#5) had EWS-FLI1 type 2 transcripts. Patient 22 had an EWS-FLI1 fusion in which 
EWS exon 7 was joined in frame with exon 7 of FLI1, and patient 2 had EWS-ERG 
transcripts. 
 
Peripheral blood samples 
PB samples, when positive, showed the same transcript type as primary tumors. No 
changes in fusion transcript type were observed in any patient throughout the study. All 
patients had at least one positive PB sample (Table 2, Fig. 2). Seventy-seven samples 
had EWS-FLI1/ ERG transcripts (Table 2). Thirty-six of 113 PB samples studied (32%) 
did not show any chimeric transcript; all of these PB samples corresponded to patients 
with EWSFU] type 1 transcripts in the primary tumor. 
 
 
Clinical Outcome 
 
Median follow-up time as of March 1, 1998 was 26 months (mean, 35 months; range 5 
to 110). At that time, 20 of 28 patients (15 of 23 with localized disease and all patients 
with metastatic disease) had finished the entire treatment protocol (12 months); the 
remaining 8 patients were still being treated. Three patients of the 23 with localized 
disease and 4 of 5 with metastatic disease showed progression. Four patients died from 
disease: patient 1 at 14 months after diagnosis, patient 2 at 18 months, patient 5 at 57 
months, and patient 22 at 42 months. 
  
  
Molecular Results and Clinical Parameters 
  
Molecular results are displayed in Figure 2 in relationship with stage and status of 
disease. In 5 patients whose initial sample was positive, subsequent samples were 
negative (Fig. 3). In another 6 patients, positive and negative results alternated. In 
patients with tumor progression, all samples taken during progression were positive 
(Fig. 4). Four patients had positive samples before progression was clinically evident; 
the time elapsed between positive samples and progression was 2, 14, 34, and 36 
months (Fig. 2). All three patients with transcripts other-than EWS-FLI1 type 1 
(patients 2, 5, and 22) showed clinical progression and died from disease; patients 2 and 
5 had metastatic disease at diagnosis and patient 22 with a 7-7 fusion had localized 
disease at diagnosis. Transcript type other than EWS-FLI1 type 1 was more frequently 
associated with progression (p = 0.01, Pearson chi-square with continuity correction) 
(Table 3). 
 
Forty-six of 82 samples (56%) taken from patients with clinical remission were 
positive; in patient 28, two positive samples were observed 8 y after the end of therapy. 
However, positive samples were more prevalent in patients with progression (28 of 32; 
88%) (p = 0.04, Pearson chi-square with continuity correction). Positive samples were 
more frequently found among patients with metastatic disease at diagnosis (21 of 23; 
91%) than in patients with localized disease (56 of 90; 62%) (p = 0.01, Pearson chi-
square with continuity correction). 
  
 
Histologic Response to Therapy, Tumor Size, and Molecular Results 
 
Complete histologic study could be performed in 20 patients for whom resected tumors 
were available. Eight tumors had grade 3 response, 10 had grade 2 response, and 2 had 
grade 1 response. The first PB sample after tumor resection (14 weeks) was positive in 
all patients with grade 1 and 2 responses, and in 5 of 6 patients with grade 3 response. 
Moreover, the degree of response to chemotherapy was not associated to any given 
pattern of molecular results (i.e. positive samples that became negative, alternating 
results, and samples that remained negative) (results not shown). 
 
Mean tumor volume was 98 ml (range, 6 to 550 ml). Tumor volumes of patients with 
metastasis at diagnosis were higher than those with localized disease (276 versus 57 ml; 
p = 0.04). Tumor volume in patients in whom samples became negative with treatment 
was not significantly different from that of patients in whom samples remained positive 
(152 versus 40 ml, respectively; p = 0.43). 
 
 
DISCUSSION 
 
The role of pathologists in the management of ET is the accurate diagnosis and 
assessment of tumor necrosis after initial treatment (19,25). Detection of specific 
chimeric transcripts, already a useful routine assay in molecular pathology for the 
diagnosis of small cell developmental tumors (3,7,13,22), makes ET a good model to 
study minimal residual or metastatic disease (4,6,8,17, 18,24,27). 
 
ET-specific fusion transcripts can become undetectable by RT-PCR assay during 
therapy, as occurred in 5 patients in this series. In one of these patients, samples 
remained negative during a follow-up of 2 y. All negative PB samples corresponded to 
patients that had complete remission at that time, a finding of clinical and biological 
value. 
 
Transcript detection occurred in all patients with disease progression. Moreover, four 
patients had positive samples several months before progression was clinically evident. 
Similar results have been already reported in several types of leukemia (20), suggesting 
that patients with repeated positive samples have a high probability for disease 
progression. These findings may have clinical implications, and therapy can be 
intensified in ET patients at high risk for disease progression. Ongoing quantitative RT-
PCR assays probably will help to further assess the prognostic value of transcript 
detection. 
 
Several patients maintained positive results after the end of therapy. Moreover, 
transcripts were still detectable in a few patients with a good clinical response to 
therapy. This is remarkable because most of them are considered to be in complete 
remission, and one of these patients has been off therapy for 8 y. Several authors 
reported sustained positive RT-PCR results (AML-ETO transcripts) even 8 y after 
induction of therapy in a few patients with acute myeloid leukemia (14). The consistent 
presence of transcripts in PB samples of patients in complete remission may represent 
tumor cells under the control of the immune system (1), or may indicate that another 
molecular event is needed to become metastatic. The high sensitivity of nested RT-PCR 
followed with Southern blot could allow detection of an amount of cells hypothetically 
too small to cause a relapse. Moreover, disappearance of tumor cells may not be a 
prerequisite for cure, as shown in a study using a quantitative assay in patients with 
childhood acute lymphoblastic leukemia (20). Because RNA is unstable and short-lived 
in the extracellular environment, the presence of RT-PCR positivity probably indicates 
intact tumor cells. Alternating results were seen in severa] patients, possibly because the 
number of circulating tumor cells may be close to the detection threshold of the RT-
PCR assay, as described in acute lymphoblastic leukemia (16). 
 
Tumor cells could be detected in our series after tumor resection regardless of stage at 
diagnosis, although they were detected more frequently in patients with metastatic 
disease at diagnosis, as previously reponed (6,27). These data confirm that ET is a 
disseminated disease at diagnosis. Of note, the first samples taken after resection of 
tumor were frequently positive, even in patients with complete tumor necrosis, 
suggesting that tumor cells remain present in PB even in patients with complete 
responses to induction therapy. This represents further biological evidence supporting 
the need for systemic therapy after resection of the tumor. Detection of ET transcripts 
was independent of tumor volume, indicating that transcript detection in PB samples 
may not be a function of initial tumor burden, in contrast to the suggestions of several 
authors (27). 
 
Fusion transcripts in ET show a considerable molecular heterogeneity at the level of 
exonic structure and in the involved ETS genes (31). We and others have recently 
shown that patients with ET with EWS-FLI1 transcripts other than type 1 have a worse 
prognosis (2,28) regardless of stage, tumor location, or age (2). However, the biological 
basis for this phenomenon is unclear and could include secondary molecular alterations 
in genes regulating cell cycle (12), drug resistance, or ability to metastasize. In the 
present study, patients with transcripts other than EWS-FLI1 type 1 repeatedly had 
positive samples, tumor progression, and death from disease in a short time. Moreover, 
all negative samples (36 of 113; 32%) were taken from patients with EWS-FLI1 type 1 
fusions in the primary tumor and in initial PB samples. This is consistent with our 
previous results (2), and suggests the clinical usefulness of transcript detection in PB 
samples of patients with ET. Although the number of patients in our series with 
transcripts other than EWS-FLI1 type 1 is small, our results suggest that presence of 
circulating tumor cells may not only depend on the tumor burden (quantitative factors), 
but also on the specific transcript variants (qualitative factors). 
 
Whether PB samples or BM specimens are the best source to detect minimal residual 
disease in ET is a matter of discussion. One report describes BM as the most sensitive 
source (6). Nevertheless, BM involvement in ET is probably multifocal, and the amount 
of minimal residual disease can vary in BM samples obtained from different sites 
(10,11,15). From a practical point of view, this approach requires extensive BM 
investigation with several samples taken every few months. Moreover, disagreement 
exists to whether BM involvement at diagnosis measured by RT-PCR has prognostic 
value (8,29). Study of PB samples is probably more convenient for patients with ET 
because they are usually subjected to monitoring of blood counts during and after 
completion of therapy. A potential limitation of PB samples was reported by Zoubek et 
al. (30), who showed detection of ET cells in PB samples during open biopsies, but not 
before and after 6 days after surgery. Based on their results, we think that detection of 
ET cells 2 weeks after resection in our study was not caused by tumor cell mobi 
lization. 
 
Circulating tumor cells can be detected in PB samples of patients with ET. Although 
further studies with longer follow-up, BM samples, and quantitative techniques are 
warranted to assess the clinical value of this assay, our initial data suggest that it might 
be a useful additional approach to monitor therapy and may help to predict disease 
progression.  
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Table 1. Sequences of primers and probes used in the molecular assays 
First PCR EWS 22.3 5-TCCTACAGCCAAGCTCCAAGTC-3' 
 FLI1 11.3 5-ACTCCCGTTGGTCCCCTCC-3' 
 ERG 3 5'-ACTCCCCGTTGGTGCCTTCC-3' 
Nested PCR EWS 22.4 5'-CCAACAGAGCAGCAGCTAC-3' 
 FLI1 11.4 5'-CAGGTGATACAGCTGGCG-3' 
 ERG 4 5'-CAGGTGATGCAGCTGGAG-3' 
Probes EWS 22.6 5'-CAGAGCAGCAGCTACGGGCAGC-3'
 FLI1 11.6 5'-TGCCACAGCTGGATCTG-3' 
 
 
 
 
 
Table 2. Chimeric transcripts found in primary tumors              
and in PB samples 
Transcript type Primary tumor PB samples 
EWS-FLI1 type 1 25 61 
EWS-FLI1 type 2 1 9 
EWS-FLI1 fusion 7-7 1 6 
EWS-ERG 1 1 
Negative 0 36* 
Total 28 113 
* All negative samples correspond to patients that had EWSFLI1   
type 1 fusions in primary tumors. 
 
 
 
 
Table 3. Patients with tumor progression, and transcript type 
Transcript type No progression Progression Total 
EWS-FLI1 type 1 21 4 25 
All other types 0 3 3 
Total 21 7 28 
p = 0.01, Pearson's chi-square with continuity correction. 
 
 
 
 
 
 
 
 
 
Figure 1. Treatment protocol and sample schedule. Arrows indicate sample timing. 
 
 
 
 
 
 
 
 
 
Figure 2. Molecular results with respect to stage and clinical status. Follow-up of 
patients is represented in a bar histogram in which the horizontal axis represents time. 
Filled segments of the bars represent complete remission, while open segments 
correspond to tumor progression. The first 12 months represent treatment. 
 
 
 
 
 
 
 
 
Figure 3. Southem blots of patients on treatment. Patient in lane 2 had a sample with 
EWS-FLI1 type 1 transcripts 4 weeks after tumor resection that became negative (lane 
3) 2 months later (patient 20 in Fig. 2). Sample in lane 4 corresponds to patient 22 10 
months from diagnosis. Sample in lane 5 was taken from patient 13 6 months after 
diagnosis. Lane 6 corresponds to a patient in whom samples remained positive during 
treatment (patient 21 in Fig. 2). 329 bp is the expected size for a EWS-FLI1 type 1 
transcript. C, positive control; lane 1, negative control. Blot has been hybridized with 
FLI1 11.6 probe. 
 
 
 
 
 
 
Figure 4. Southern blots of patients after treatment. Samples of patients in remission are 
analyzed in lanes 2 to 4. Patient in lane 4 (patient 21) shows a faint band corresponding 
to a EWS-FLI1 type 1 transcript. Patients in lanes 5 and 6 (patients 1 and 5 in Fig. 2, 
respectively) showed progression of disease. Patient in lane 6 shows a 395-bp band 
corresponding to a EWS-FLI1 type 2 fusion. Additional faint bands in lanes 5 and C 
presumably represent PCR artifacts. The expected size for a EWS-FLI1 type 1 transcript 
is 329 bp. C, positive control; lane 1, negative control. Blot has been hybridized with 
FLI1 11.6 probe.  
 
